Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro ) in Growth Hormone Treatment na ve Pre-pubertal Children With Growth Hormone Deficiency

  • STATUS
    Recruiting
  • End date
    Aug 26, 2024
  • participants needed
    74
  • sponsor
    Novo Nordisk A/S
Updated on 7 December 2021

Summary

This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 (somapacitan) treatment compared to daily growth hormone treatment (Norditropin FlexPro) in growth hormone treatment nave pre-pubertal children with growth hormone deficiency.

The trial consists of a 26 week main trial period, followed by a 26 week extension trial period, a 104 week safety extension period, a 208 week longterm safety extension trial period and a 30 day follow up period. Participants receive NNC0195-0092 (somapacitan) (0.04 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods. Two additional age groups, cohort II (age below 2 years and 26 weeks at screening) and cohort III (above 9 years (girls)/ above 10 years (boys) and equal to or below 17 years at screening) are included in the 208 week long-term safety extension trial period only.

Details
Condition Growth Hormone Disorder, Growth Hormone Deficiency in Children
Treatment Somapacitan, NNC0195-0092, Norditropin® FlexPro® pen
Clinical Study IdentifierNCT02616562
SponsorNovo Nordisk A/S
Last Modified on7 December 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Cohort I
Boys: Tanner stage 1 for pubic hair and testis volume below 4 ml , age at least 2 years and 26 weeks and below or equal to 10.0 years at screening
Girls: Tanner stage 1 for breast development (no palpable glandular breast tissue) and pubic hair, age at least 2 years and 26 weeks and below or equal to 9.0 years at screening
Confirmed diagnosis of GHD (growth hormone deficiency) within 12 months prior to screening as determined by two different GH (growth hormone) stimulation tests, defined as a peak GH level of below or equal to 7.0 ng/ml. For children with three or more pituitary hormone deficiencies only one GH stimulation test is needed
No prior exposure to GH therapy and/or IGF-I (insulin-like growth factor I) treatment
Height of at least 2.0 standard deviations below the mean height for chronological age (CA) and gender according to the standards of Centers for Disease Control and Prevention 2-20 years: Girls/Boys stature-for-age and weight-for-age percentiles CDC at screening
Annualized height velocity (HV) below the 25th percentile for CA (chronological age) and gender or below -0.7 SD (standard deviation) score for CA and sex, according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months
Cohort II
Below 2 years and 26 weeks and a minimum weight of 5 kg at screening
Confirmed diagnosis of GHD, the GHD diagnosis must be confirmed by investigator according to local practice
For GH treatment nave subjects, no prior exposure to GH therapy and/or IGF-I treatment
For GH treatment nave subjects, IGF-1 SDS below -1.0 at screening, compared to age and sex normalized range according to central laboratory measurements
Cohort III
Age
Girls: Above 9 years and below or equal to 17 years at screening
Boys: Above 10 years and below or equal to 17 years at screening
Confirmed diagnosis of GHD
for GH treatment nave subjects, confirmed diagnosis within 12 months prior to screening as determined by two different GH stimulation tests, defined as a peak GH level of equal to or below 7.0 ng/ml. For children with three or more pituitary hormone deficiencies only one GH stimulation test is needed. FOR JAPAN ONLY: Confirmed diagnosis of GHD within 12 months prior to screening as determined by one GH stimulation tests for patients with intracranial organic disease or symptomatic hypoglycaemia and two different GH stimulation test for other patients, defined as a peak GH level of equal to or below 6 ng/ml by assay using recombinant GH standard
for non-GH treatment nave subjects, confirmed GHD diagnosis by investigator according to local practice
For GH treatment nave subjects, no prior exposure to GH therapy and/or IGF-I treatment
Open epiphyses; defined as bone age below 14 years for females and bone age below 16 years for males

Exclusion Criteria

Any clinically significant abnormality likely to affect growth or the ability to evaluate
growth with standing/length measurements: Chromosomal aneuploidy and significant gene mutations causing medical "syndromes" with short stature, including but not limited to Turner syndrome, Laron syndrome, Noonan syndrome, or absence of GH receptors. Congenital abnormalities (causing skeletal abnormalities), including but not limited to Russell-Silver Syndrome, skeletal dysplasias. Significant spinal abnormalities including but not limited to scoliosis, kyphosis and spina bifida variants
Children born small for gestational age (SGA - birth weight and/or birth length below-2 SD for gestational age)
Concomitant administration of other treatments that may have an effect on growth (not applicable to non-GH treatment nave subjects in cohort II and III), including but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder (ADHD)
Prior history or presence of malignancy and/or intracranial tumour
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note